| Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective cohort study S Teraoka, D Fujimoto, T Morimoto, H Kawachi, M Ito, Y Sato, K Nagata, ... Journal of Thoracic Oncology 12 (12), 1798-1805, 2017 | 354 | 2017 |
| Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non–small cell lung cancer D Fujimoto, Y Sato, K Uehara, K Ishida, J Fukuoka, T Morimoto, ... Journal of Thoracic Oncology 13 (3), 377-386, 2018 | 55 | 2018 |
| Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab … G Saito, Y Oya, Y Taniguchi, H Kawachi, F Daichi, H Matsumoto, ... Lung Cancer 161, 86-93, 2021 | 38 | 2021 |
| Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective … H Kawachi, M Tamiya, A Tamiya, S Ishii, K Hirano, H Matsumoto, ... Investigational new drugs 38, 211-218, 2020 | 36 | 2020 |
| Clinical characteristics and prognosis of patients with advanced non–small-cell lung cancer who are ineligible for clinical trials H Kawachi, D Fujimoto, T Morimoto, M Ito, S Teraoka, Y Sato, K Nagata, ... Clinical Lung Cancer 19 (5), e721-e734, 2018 | 34 | 2018 |
| Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma H Kawachi, K Kunimasa, Y Kukita, H Nakamura, K Honma, T Kawamura, ... Immunotherapy 13 (10), 799-806, 2021 | 33 | 2021 |
| Comparison of PD-L1 assays in non-small cell lung cancer: 22C3 pharmDx and SP263 D Fujimoto, D Yamashita, J Fukuoka, Y Kitamura, K Hosoya, H Kawachi, ... Anticancer research 38 (12), 6891-6895, 2018 | 25 | 2018 |
| Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction K Kunimasa, T Oka, S Hara, N Yamada, S Oizumi, Y Miyashita, R Kamada, ... Lung Cancer 153, 186-192, 2021 | 19 | 2021 |
| Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients K Hosoya, D Fujimoto, H Kawachi, Y Sato, M Kogo, K Nagata, ... Cancer Chemotherapy and Pharmacology 84, 275-280, 2019 | 18 | 2019 |
| Improvement strategies for successful next-generation sequencing analysis of lung cancer K Kunimasa, S Matsumoto, K Nishino, H Nakamura, H Kuhara, M Tamiya, ... Future Oncology 16 (22), 1597-1608, 2020 | 17 | 2020 |
| Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using nivolumab H Kawachi, D Fujimoto, T Morimoto, K Hosoya, Y Sato, M Kogo, K Nagata, ... Investigational New Drugs 37, 1257-1265, 2019 | 17 | 2019 |
| Reduced tumour proportion scores for programmed cell death ligand 1 in stored paraffin tissue sections Y Sato, D Fujimoto, K Uehara, H Kawachi, K Nagata, A Nakagawa, ... Anticancer Research 38 (3), 1401-1405, 2018 | 16 | 2018 |
| Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer Y Katayama, T Yamada, K Tanimura, S Tokuda, K Morimoto, S Hirai, ... NPJ Precision Oncology 7 (1), 12, 2023 | 12 | 2023 |
| Elective nodal irradiation for non-small cell lung cancer complicated with chronic obstructive pulmonary disease affects immunotherapy αfter definitive chemoradiotherapy M Morimoto, K Nishino, K Wada, F Imamura, K Konishi, H Kuhara, ... Anticancer Research 40 (12), 6957-6970, 2020 | 10 | 2020 |
| Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study K Matsumoto, A Tamiya, Y Matsuda, Y Taniguchi, S Atagi, H Kawachi, ... Translational Lung Cancer Research 10 (4), 1642, 2021 | 9 | 2021 |
| Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval … G Saito, Y Oya, Y Taniguchi, H Kawachi, D Fujimoto, H Matsumoto, ... Journal of Clinical Oncology 38 (15_suppl), 9039-9039, 2020 | 9 | 2020 |
| Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous NSCLC with malignant pleural effusion: A retrospective multicenter cohort study H Kawachi, M Tamiya, Y Taniguchi, T Yokoyama, S Yokoe, Y Oya, M Imaji, ... JTO clinical and research reports 3 (7), 100355, 2022 | 7 | 2022 |
| Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study H Kawachi, M Tamiya, K Matsumoto, A Tamiya, T Yanase, S Tanizaki, ... Investigational New Drugs 40 (3), 634-642, 2022 | 7 | 2022 |
| Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib K Kunimasa, K Nishino, Y Kukita, S Matsumoto, H Kawachi, T Kawamura, ... Cancer Genetics 256, 57-61, 2021 | 7 | 2021 |
| Association between formalin fixation time and programmed cell death ligand 1 expression in patients with non-small cell lung cancer H Kawachi, D Fujimoto, D Yamashita, J Fukuoka, Y Kitamura, K Hosoya, ... Anticancer Research 39 (5), 2561-2567, 2019 | 7 | 2019 |
Keisuke TomiiKobe CIty Medical Center General HospitalVerified email at kcho.jp
